Health Condition 1: O80- Encounter for full-term uncomplicated delivery Health Condition 2: O80- Encounter for full-term uncomplicated delivery
Conditions
Interventions
Intervention1: Carbetocin: Injection Carbetocin 100 mcg in 9 ml of Normal Saline slow I.V
Control Intervention1: Oxytocin: Injection Oxytocin 10 IU in Ringer lactate I.V Infusion
Sponsors
Dr.Saranya,Postgraduate in Obstetrics and gynaecology
Eligibility
Inclusion criteria
Inclusion criteria: Pregnant women in age group 18-35 years 1. Singleton pregnancy 2. Term (37-42 weeks of gestation) 3. Women who undergo vaginal delivery 4. Patients willing to give informed consent
Exclusion criteria
Exclusion criteria: High risk pregnant women including: antepartum hemorrhage- placenta previa, abruptio placentae, preeclampsia, eclampsia, GDM A2, multiple pregnancies, post cesarean pregnancy, polyhydramnios, macrosomia, patients with gynecological disorders such as myomas ? Medical disorders: coagulation disorders, thrombocytopenia (platelets disorders, hepatic disorders, heart disease, asthma, epilepsy, women with HIV ? Intellectual challenged women ? Known allergy to carbetocin ? Patients not willing to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uterine tone and vaginal bleeding immediately and at 1, 2, 3 hours post delivery in both the groups 1.Estimated blood loss (ml) and PPH (blood loss 500 ml) in both study groups 2. Need for use of additional uterotonic drugs and/or blood transfusion in both the groupsTimepoint: 1-3 Days after Randomization | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in value of hemoglobin, Hematocrit and Packed cell volume (PCV)Pre and 24 -hour post-delivery in both the groups ? Drug related adverse effects such as nausea, vomiting, shivering, headache, anaphylaxis in both the groupsTimepoint: 1-3 Days after Randomization | — |
Countries
India
Contacts
Public ContactDr Sharmila V
AIIMS Mangalagiri
Outcome results
None listed